Skip to content

NIH PET and SPECT Ligands Guide

Updated 6 official sources

Quick Answer: PAR-25-036 expired on May 8, 2026; its last listed due date was May 7, 2026, and NIH hadn't posted a reissue as of October 9, 2026.

Full answer and how we checked it

If a reissue appears, eligibility will likely turn on the same 7 checks: CNS-disorder relevance, unmet target need, ligand-development rationale, imaging feasibility, biomarker role, clinical-trial boundary, and R01 readiness.

Who this is for: CNS biomarker teams, PET and SPECT imaging researchers, tracer-development groups, drug-discovery teams, translational neuroscience investigators, and sponsored-research offices deciding whether PAR-25-036 is the right NIH route.

Data note: This guide uses the official NIH PAR-25-036 NOFO, Grants.gov listing 357006, NIH clinical-trial policy pages, Grants.gov records of earlier versions, and NIH RePORTER award records, rechecked October 9, 2026.

In this guide

Quick Facts

Agency
HHS
Last deadline
May 7, 2026 (passed)
Status
Closed

Assistance Listing 93.866: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.866, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
10,364
Avg Award (whole listing)
$3,365,037
Median Award (whole listing)
$1,781,166
Total Funding (FY2024, whole listing)
$3.8B
YoY Funding Trend
-0.1%

Data last verified: May 19, 2026

According to NIH PAR-25-036 (opens in a new tab), this NOFO supports development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and pathophysiological studies of CNS disorders. NIH listed the activity code as R01 and marked clinical trials as optional. The notice now carries NIH's "This notice has expired" banner.

This route is not for every imaging study. The core question is whether the project advances a PET or SPECT ligand as a meaningful CNS biomarker, not whether imaging is useful somewhere inside the project.

Use this guide with the live Grantsights program record. Then compare NIH grants complete guide, what is a NOFO, NHLBI clinical trial pilot guide, NINDS U01 renewal guide, and the Grantsights grant database.

7 PAR-25-036 Eligibility Stop Checks

Stop checkStrong PAR-25-036 signalRed flag
CNS relevanceCNS disorder biology is centralTarget is not CNS-relevant
Target needHuman PET tracer need is clearExisting ligand is enough
Ligand rationaleChemistry, binding, and specificity path are credibleLigand plan is speculative
Imaging feasibilityPET or SPECT method is justifiedImaging is routine support
Biomarker roleDrug discovery or pathophysiology use case is specificBiomarker endpoint is vague
Clinical-trial boundaryOptional trial status is handled correctlyTrial work is hidden or unclear
R01 readinessMulti-year research plan is matureBetter fit is R21, R61/R33, or tool-development route

Imaging proposals can weaken when the tracer is treated like a service component. In this NOFO, the ligand-biomarker story needs to be the point.

5 Source Facts Applicants Should Know

According to NIH, PAR-25-036 supports PET and SPECT imaging ligands as biomarkers for drug discovery and pathophysiological studies of CNS disorders.

According to NIH, interested parties are encouraged to contact the appropriate NIH Program Officer to discuss the perceived level of need for a particular human PET tracer. NIH marks the NOFO as R01 Clinical Trial Optional.

According to USAspending.gov (opens in a new tab) data, assistance listing 93.866 had about $3.83B in FY2024 obligations across 10,364 awards active that year.

FactSource-backed read
Funding numberPAR-25-036
Activity codeR01
Clinical trial statusClinical Trial Optional
StatusExpired May 8, 2026; no reissue posted as of Oct 9, 2026
Participating ICsNIMH and NIA
Budget and periodNot capped; up to 5 years
Live listingGrants.gov listing 357006

Where This NOFO Stands Now

Grants.gov search records (opens in a new tab) show this program has been reissued under new numbers repeatedly since 2006: PA-06-461 through PA-06-463, PAR-10-024, PAR-13-158, PAR-16-266, PAR-18-227, PAR-20-037 and PAR-20-038, PAR-23-164 and PAR-23-165, and then PAR-25-036. That history suggests NIMH and NIA may reissue it again, but no forecast or new NOFO was listed on October 9, 2026, so treat that as a possibility, not a date.

Until then, a CNS radiotracer project can still go to an open parent announcement. The NIH Parent R01, Clinical Trial Not Allowed (PA-25-301) (opens in a new tab) runs through January 7, 2028, and PA-25-305 covers R01s that require a clinical trial. Standard dates apply: new R01s are due February 5, June 5, and October 5, and resubmissions March 5, July 5, and November 5. The parent route loses the NOFO's targeted language, so email the NIMH or NIA program officer named in PAR-25-036 about fit and institute interest before you write. The NIH R01 research project grant guide covers parent R01 mechanics, and the R01 vs R21 vs R03 comparison helps if the tracer work is still early enough for a 2-year exploratory grant.

What the NOFO Asked Reviewers to Weigh

PAR-25-036 used NIH's simplified review framework with NOFO-specific additions, and those are the best guide to what a reissue will ask:

  • Importance: reviewers evaluate the justification for a radiotracer for the target or cellular process, its intended uses, and the questions it would let the field answer.
  • Rigor and feasibility: how well the application shows the target can be detected in the brain regions of interest, the desired tracer properties, and the plan and timeline to reach them.
  • Expertise and resources: whether a biological collaborator or advisor who'd actually use the tracer is involved in choosing the target.

Two scope rules sit in the NOFO text. A feasibility assessment, such as target density and affinity in post-mortem human brain or a published reference for it, had to exist before submitting a tracer discovery project. And NIH flagged limited interest in another tracer for a target class already in its CNS Radiotracer Table unless you make a compelling case. NIH also named agonist and allosteric-modulator ligands, plus tracers for neuroinflammation, synaptic integrity, and mitochondrial function, as of particular interest, and it encouraged pharmaceutical scientists to join as PIs or key personnel.

What Funded Projects Looked Like

Grantsights checked the NOFO numbers against NIH RePORTER (opens in a new tab) records pulled October 9, 2026. Grantsights analysis of those records found few awards under these numbers. A real-world example: under PAR-25-036, NIA funded St. Jude Children's Research Hospital's pro-drug imaging agents to detect neuroinflammation in Alzheimer's disease (1R01AG093113-01A1, $758,781 in FY2026). Under the earlier PAR-23-165, NIMH funded McLean Hospital's D2high receptor imaging project (R01MH134074), which received $666,559 in FY2026, its third year. Both were funded on a resubmission (A1), and both target a defined CNS process. Under PAR-20-038, NIA funded a first-in-human evaluation of an astrocytic glutamate transporter tracer at UC San Francisco (1R01AG072743-01A1, $784,058 in FY2022) and Memorial Sloan Kettering's [18F]-PU-AD epichaperome PET probe as an RF1 (1RF1AG071805-01A1, $3,589,781). The common thread is a named molecular target with a clear disease question. A thin award record also means a program officer conversation before writing matters more, not less: with so few slots, a project the institute doesn't see as a priority target is a weak bet even if the chemistry is strong.

What NIH Doesn't Tell You

Within 21 days, answer 4 practical questions. First, ligand need must be argued, not assumed. If a field already has adequate human tracers, the team needs a sharper rationale.

Second, the path from chemistry to biomarker should be concrete. A team developing a CNS PET ligand with a target-engagement use in drug discovery has a clearer route than a team using PET as an exploratory add-on.

Third, clinical-trial optional does not mean trial details can be vague. If human studies are included, the application needs human-subjects, statistical, safety, and imaging-readiness detail.

Fourth, NIMH asked for Common Data Elements in mental health human subjects research and budgeted data submission to the NIMH Data Archive, so human imaging projects routed to NIMH should plan for that cost.

6 Evidence Assets That Make This Proposal Stronger

Within 21 days, build 6 evidence assets. Asset 1 is the target-need memo. Explain the CNS target, disorder context, current tracer gap, and why a new or improved ligand matters.

Asset 2 is the ligand-readiness plan. Include chemistry, binding, selectivity, metabolism, dosimetry when relevant, and species translation.

Asset 3 is the biomarker-use memo. State whether the ligand supports drug discovery, target engagement, disease biology, stratification, progression, or treatment-response work.

Asset 4 is the imaging protocol plan. Include PET or SPECT method, acquisition, quantification, reproducibility, scanner or site plan, and analysis.

Asset 5 is the clinical-trial boundary memo. State whether the proposal includes an NIH-defined clinical trial and why.

Asset 6 is the route memo. Compare PAR-25-036 with R21, R61/R33, device or assay development routes, NINDS, NIA, NIMH, NIDA, NHLBI, and private translational funding.

5 Route Choices Before Drafting

Within 21 days, compare 5 routes.

RouteBetter first read when...Why
PAR-25-036 reissuePET/SPECT ligand biomarker project is matureWatch for a new number
Parent R01 (PA-25-301)Project is ready nowOpen through Jan 7, 2028
R21Early feasibility dominatesSmaller route may fit
R61/R33Milestone-driven development dominatesPhased route may fit
Clinical trial NOFOTrial endpoint dominatesTrial route may fit
Private or pharma routeTarget-engagement assay is product-facingNon-NIH route may fit

Warning: if the ligand could be removed and the science still works, don't start with PAR-25-036.

6 Bad-Fit Signals

First, the target is not tied to CNS disorders. Second, ligand need is not clear. Third, PET or SPECT is routine support.

Fourth, the proposal lacks preclinical or human feasibility logic. Fifth, clinical-trial status is unclear. Sixth, the project is too early for an R01.

These signals are route risks.

21-Day PET/SPECT Ligand Readiness Plan

Days 1 through 3 should confirm target need, CNS-disorder relevance, clinical-trial status, and route alternatives. Days 4 through 7 should write the target-need and ligand-readiness memos.

Days 8 through 12 should build biomarker-use and imaging-protocol plans. Days 13 through 16 should check human-subjects, trial boundary, budget, team expertise, and program officer questions. Days 17 through 21 should complete NIH application checks and route proof.

6 Final Research Checks Before Submission

Within 21 days, finish 6 final checks. Check 1 is the NIH PAR-25-036 NOFO (opens in a new tab). Check 2 is NIH clinical trial policy (opens in a new tab). Check 3 is CNS target need. Check 4 is ligand feasibility. Check 5 is biomarker use. Check 6 is clinical-trial boundary.

You're ready when the team can state the CNS target, ligand gap, imaging method, biomarker use, clinical-trial status, and route reason in 6 direct sentences.

4 Decision Questions Before You Commit

Within 21 days, ask 4 decision questions. Question 1: "What CNS target needs a PET or SPECT ligand?" Question 2: "What biomarker decision will the ligand support?" Question 3: "Is a clinical trial included?" Question 4: "Is the project mature enough for R01 review?"

If question 1 is weak, redirect before the team writes aims.

3 Last-Mile Checks For Imaging Teams

Within 21 days, run 3 last-mile checks. Check 1 is target proof. Check 2 is ligand proof. Check 3 is biomarker proof.

If those checks are weak, a program officer conversation may save the route. A final note for applicants: write the PAR-25-036 fit sentence before the Specific Aims page. In 2 sentences, state the CNS target, ligand gap, imaging method, biomarker use, and reason this R01 is the best route.

Sources

Largest awards active in FY2024

One row per recipient, its largest award | 10,364 Assistance Listing records | Avg: $3.4M

REAL DATA
1

University of California, Los Angeles

CA

$996.1M
2

Regents of the University of Michigan

MI

$463.4M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Frequently Asked Questions

What does PAR-25-036 support?

It supported development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and pathophysiological studies of CNS disorders. NIH lists it as expired on May 8, 2026, and no reissue was posted as of October 9, 2026.

What activity code applies?

NIH listed R01 for this NOFO, with NIMH and NIA participating. Budgets weren't capped, and project periods could run up to 5 years.

Are clinical trials allowed?

Yes. NIH marks the NOFO as Clinical Trial Optional.

What should teams prove before applying?

Teams should prove target need, ligand rationale, imaging feasibility, biomarker use case, CNS-disorder relevance, and translational path.

Who should skip this route?

Skip it when the ligand is not tied to a CNS target or biomarker question, or when the project is only routine imaging support.

Last updated October 9, 2026. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.